Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888340 | 0.99 | S1PR1 (0.59) | S1PR1LMNAMAPTCYP1A2TP53 | |
| SCHEMBL4523671 | 0.94 | LMNA (0.54) | S1PR1LMNAMAPTCYP1A2TP53 | |
| SCHEMBL4176314 | 0.92 | S1PR1 (0.58) | S1PR1LMNAMAPTTP53SMN1; SMN2 | |
| SCHEMBL3949029 | 0.92 | S1PR1 (0.58) | S1PR1LMNAMAPTTP53KMT2A | |
| SCHEMBL3885678 | 0.92 | LMNA (0.58) | S1PR1LMNAMAPTCYP1A2TP53 | |
| SCHEMBL3889085 | 0.92 | S1PR1 (0.50) | S1PR1LMNAMAPTTP53SMN1; SMN2 | |
| SCHEMBL4515819 | 0.89 | S1PR1 (0.48) | S1PR1LMNAMAPTCYP1A2TP53 | |
| SCHEMBL4511085 | 0.89 | S1PR1 (0.48) | S1PR1LMNAMAPTCYP1A2TP53 | |
| SCHEMBL3885614 | 0.89 | S1PR1 (0.47) | S1PR1LMNAMAPTCYP1A2TP53 | |
| SCHEMBL4530138 | 0.88 | S1PR1 (0.57) | S1PR1LMNAMAPTTP53CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | S1PR1 3084/4885LMNA 4113/4885MAPT 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.